



IN THE CLAIMS:

Please cancel claims 19 and 21 without prejudice and amend the claims as follows:


1. (Original) Pharmaceutical or diagnostic composition comprising one or more active substances wherein the one or more active substance is/are selected from a group consisting of:
 - (a) active substances with a structure according to formula I-1 to I-9




Formula I-1




Formula I-2




Formula I-3




Formula I-4




Formula I-5




Formula I-6



Formula I-7




Formula I-8




Formula I-9

wherein X in formula I-2 and I-3 is H, OH, NH₂ or a halogen atom and X₁ and X₂ in formula I-4 are any heteroatom;

(b) active substances with a structure according to formula II-1 or II-2




Formula II-1



Formula II-2


(c) active substances with a structure according to formula III-1 to III-6




Formula III-1




Formula III-2



Formula III-3



Formula III-4




Formula III-5




Formula III-6

wherein X in formula III-1 and X₁ and X₂ in formula III-5 are H, OH, NH₂ or a halogen atom;


(d) active substances with a structure according to formula IV-1 to IV-6




Formula IV-1




Formula IV-2




Formula IV-3



Formula IV-4




Formula IV-5




Formula IV-6

X₁ and X₂ in formula IV-6 are selected from H, F, I, Br or Cl, OH or OA, SH or SA, NH₂, NHA₁ or NA₁A₂ or A and wherein A and/or A₁ and A₂ is/are a branched, straight-chain or cyclic alkyl or heteroalkyl group with up to 7 carbon atoms;


(e) active substances with a structure according to formula V-1 to V-4




Formula V-1



Formula V-2




Formula V-3




Formula V-4

(f) active substances with a structure according to formula VI-1 or VI-2



Formula VI-1



Formula VI-2


wherein R₁ to R₉ and S₁ to S₃ are selected from

- (i) H, OH, NH₂ or a halogen atom;
- (ii) single- or multi-branched or straight-chain alkyl or heteroalkyl groups with one or two rings and up to 10 carbon atoms;
- (iii) cyclic alkyl or heteroalkyl groups with 1 or 2 rings or aryl or heteroaryl groups with up to 10 carbon atoms each.


2. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the halogen atoms are selected from the group consisting of I, Cl, Br and F.
3. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 heteroatoms each.
4. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 3, wherein the heteroatoms are selected from a group consisting of N, O, and S.
5. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 substituents each.
6. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 5,

wherein the substituents are selected from a group consisting of Cl, F, Br and I.


7. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein R₁ and R₂, R₂ and R₃, R₃ and R₄, R₄ and R₅, R₅ and R₆, R₆ and R₇, R₇ and R₈ and/or R₈ and R₉ are bridged via further atoms.
8. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-5 or I-7 is selected from:



Anthraquinone




1,8-Dihydroxy-anthraquinone (Danthron)




1,8-Dihydroxy-10H-anthracene-9-one

(Dithranol/ Anthralin)




1,8-Dihydroxy-3-methyl-10H-anthracene-9-one


(Chrysarobin)



1,2,5,8-Tetrahydroxy-anthraquinone




4-[2-(1-Amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-sulfonyl)-ethyl]-N-propyl-benzensulfonamide; and




2-Amino-benzoic acid-6-(1-amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-yloxy)-hexyl-ester.


9. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-1 is selected from:




(1-Methyl-1H-perimidine-2-yl)-methanol




2-(1H-Imidazole-4-yl)-1H-perimidine




1-Ethyl-1H-perimidine




1H,3H-Perimidine-2-thione




2-Pyridine-3-yl-1H-perimidine




1,2-Dimethyl-1*H*-perimidine




4-(1*H*-Perimidine-2-yl)-benzonitrile



2-*p*-Tolyl-1*H*-perimidine




3-(1H-Perimidine-2-yl)-phenylamine; and



2-Pyridin-4-yl-2,3-dihydro-1H-perimidine


10. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula 1-2 is




8-Fluoro-1,2-dimethyl-4,5-dihydro-pyrrolo[3,2,1-ij]quinoline-6-one.

11. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1,


wherein the active substance with a structure according to formula 1-4 has the following formula:




12. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 11, wherein the active substance is selected from




Phenoxazine-3-one




1,9-Dimethyl-phenoxazine-3-one




7-Amino-1,9-dimethyl-phenoxazine-3-one




7-Hydroxy-1,9-Dimethyl-phenoxazine-3-one




7-Amino-8-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one
(alpha-amino-orcein)




8-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one
(alpha-hydroxy-orcein)




7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one
(beta-amino-orcein)




7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one
(gamma-amino-orcein)




2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one
(beta-hydroxy-orcein)



2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one
(gamma-hydroxy-orcein)




beta-amino-orceimine; and




gamma-amino-orceimine.


13. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula II-2 is selected from:




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylaminoethyl)-formamide




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylaminoethyl)-acetamide




7-Oxo-2-(2-piperidin-1-yl-ethylamino)-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinolin-2-yl)-N-(3-dimethylamino-propyl)-formamide




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-acetamide




2-(3-Dimethylamino-propylamino)-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinoline-8-carbonitrile




2-[(2-Diethylamino-ethyl)-ethyl-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile



2-Amino-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile



2-[4-(3-Hydroxy-propyl)-piperazine-1-yl]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile; and



2-[Benzyl-(2-dimethylamino-ethyl)-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile;

14. (Withdrawn) The diagnostic composition according to claim 1, wherein the active substance or at least one of the active substances is labeled.
15. (Cancel)
16. (Withdrawn) The pharmaceutical or diagnostic composition according to claim 1, wherein the pharmaceutical or diagnostic composition furthermore comprises one or more pharmaceutically acceptable carriers, diluents or excipients.

17. (Currently Amended) A method for the treatment or diagnosis of ~~neurodegenerative disorders or amyloid diseases~~ a polyglutamine disease comprising administering a pharmaceutical or a diagnostic composition according to claim 1 to a subject.
18. (Previously Presented) The method according to claim 17, wherein the subject is a human being.
19. (Cancel)
20. (Currently Amended) The method according to claim 19, wherein ~~the Parkinson's syndrome encompasses idiopathic Parkinson's disease as well as atypical Parkinson's syndromes associated with protein aggregation; and the~~ polyglutamine diseases ~~encompass~~ disease comprises Huntington's chorea, spinocerebellar ataxias of types 1, 2, 3, 6, 7 and 17, dentatorubral pallidoluysian atrophy ~~as well as or~~ spinobulbar muscular atrophy (Kennedy syndrome).
21. (Cancel)
22. (Withdrawn) The diagnostic composition according to claim 14, wherein the labeled active substance is radioactive-labeled.